Literature DB >> 18701416

Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.

Omar Hameed1, Amy L Adams, Allyson C Baker, Nicole E Balmer, Walter C Bell, Holly N Burford, David C Chhieng, Nirag C Jhala, Michael J Klein, Thomas Winokur.   

Abstract

The effect of using a 30% cutoff for the proportion of HER2+ cells on the interobserver variability in the interpretation of HER2 immunohistochemical results was evaluated. Immunostained sections from 96 cases of breast carcinoma were reviewed by 10 pathologists and scored as positive (3+) when uniform strong membranous staining was identified in at least 10% of tumor cells; the actual percentage of cells with such staining was also estimated. The agreement rates and the kappa values using a 30% cutoff were compared with those using a 10% cutoff. These proved to be higher in 62% and 66% of measurements, respectively, with average interobserver rates and kappa values of 72% and 0.54 using the 30% cutoff and 70% and 0.49 using the 10% cutoff (P=.001 for all comparisons). Using a 30% cutoff for the percentage of HER2+ cells by immunohistochemical analysis modestly decreased interobserver variability in the interpretation of HER2 immunohistochemical results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18701416     DOI: 10.1309/KETM3HANLUQHW7YV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  The value of thioredoxin family proteins and proliferation markers in dysplastic and malignant gallbladders in patients with primary sclerosing cholangitis.

Authors:  Karouk Said; Hans Glaumann; Mikael Björnstedt; Annika Bergquist
Journal:  Dig Dis Sci       Date:  2012-02-28       Impact factor: 3.199

2.  Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.

Authors:  Jeffrey S Larson; Laurie J Goodman; Yuping Tan; Lisa Defazio-Eli; Agnes C Paquet; Jennifer W Cook; Amber Rivera; Kristi Frankson; Jolly Bose; Lili Chen; Judy Cheung; Yining Shi; Sarah Irwin; Linda D B Kiss; Weidong Huang; Shannon Utter; Thomas Sherwood; Michael Bates; Jodi Weidler; Gordon Parry; John Winslow; Christos J Petropoulos; Jeannette M Whitcomb
Journal:  Patholog Res Int       Date:  2010-06-28

3.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

4.  IGF-IR: a new prognostic biomarker for human glioblastoma.

Authors:  C Maris; N D'Haene; A-L Trépant; M Le Mercier; S Sauvage; J Allard; S Rorive; P Demetter; C Decaestecker; I Salmon
Journal:  Br J Cancer       Date:  2015-08-20       Impact factor: 7.640

5.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

6.  Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer.

Authors:  Lisa Vermij; Naveena Singh; Alicia Leon-Castillo; Nanda Horeweg; Jan Oosting; Joseph Carlson; Vincent Smit; Blake Gilks; Tjalling Bosse
Journal:  Histopathology       Date:  2021-07-05       Impact factor: 5.087

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.